STICHTING BURO ECNP

Their core work

ECNP (European College of Neuropsychopharmacology) is the leading European professional network for applied neuroscience and psychiatry, coordinating clinical research standards and data sharing across psychiatric disorders. They contribute to large-scale EU research consortia by providing access to their network of clinicians and researchers, facilitating patient registries, and ensuring quality standards in preclinical and clinical psychiatric research. Their work spans from biomarker identification in autism and schizophrenia to real-world evidence generation using eHealth data, biobanks, and national registries. As a professional association rather than a research lab, their value lies in convening expertise, harmonizing methodologies, and bridging the gap between preclinical findings and clinical practice across Europe.

What they specialise in

How they've shifted over time

In the early period (2016-2018), ECNP focused on foundational neuroscience mechanisms — genetics, epigenetics, brain connectivity, and the microbiome-gut-brain axis — alongside initial work on psychiatric stratification through PRISM. From 2020 onward, the focus shifted decisively toward clinical application: real-world data integration (eHealth, biobanks, registries), specific disorder populations (autism, schizophrenia, Alzheimer's), and metabolic-psychiatric comorbidities. The trajectory shows a clear move from understanding mechanisms to translating findings into clinical tools and precision medicine approaches.

ECNP is moving toward data-driven precision psychiatry, combining digital health records with biomarker research — expect future projects in AI-assisted psychiatric diagnostics and pharmacogenomics.

How they like to work

ECNP operates exclusively as a participant, never as a coordinator — consistent with their role as a professional network that contributes expertise and infrastructure rather than leading research execution. With 135 unique partners across 20 countries, they connect into very large consortia (typical of IMI2 and major RIA projects in health). This wide network makes them a valuable consortium partner for anyone needing access to the European psychiatry and neuroscience community.

ECNP has collaborated with 135 unique partners across 20 countries, reflecting their position as a pan-European professional network. Their partnerships span academic hospitals, pharmaceutical companies (via IMI2 projects), and research universities across Western and Northern Europe.

What sets them apart

ECNP is not a university or a company — it is THE European professional association for neuropsychopharmacology, giving it unmatched convening power across psychiatry research. Partnering with ECNP provides access to a continent-wide network of clinicians, researchers, and psychiatric institutions that no single university or hospital can match. For consortium builders, ECNP offers legitimacy, clinical network access, and the ability to disseminate findings directly to the professionals who will use them.

Highlights from their portfolio

• AIMS-2-TRIALS
  Largest funded project (EUR 187K to ECNP) running until 2026, part of a major IMI2 initiative to transform autism clinical trials through biomarker-driven patient stratification.
• REALMENT
  Represents ECNP's newest direction — integrating real-world eHealth data, biobanks, and national registries to understand psychiatric drug response and adverse effects at population scale.
• PRISM
  Launched ECNP's involvement in transdiagnostic psychiatric biomarker research, with PRISM 2 continuing the work — showing sustained commitment to stratified psychiatry.